Enlivex Therapeutics Ltd. (ENLV): Price and Financial Metrics

Enlivex Therapeutics Ltd. (ENLV): $1.36

0.01 (+0.74%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

C

Add ENLV to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#77 of 336

in industry

ENLV Price/Volume Stats

Current price $1.36 52-week high $4.59
Prev. close $1.35 52-week low $1.15
Day low $1.30 Volume 92,400
Day high $1.41 Avg. volume 115,919
50-day MA $1.45 Dividend yield N/A
200-day MA $1.97 Market Cap 29.11M

ENLV Stock Price Chart Interactive Chart >


Enlivex Therapeutics Ltd. (ENLV) Company Bio


Enlivex Therapeutics Ltd., a clinical stage immunotherapy company, engages in developing allogeneic drugs for immune system rebalancing. Its product candidate is Allocetra, an immunotherapy candidate, which is in Phase IIb clinical trial in patients with severe sepsis; that is in investigator-initiated Phase II clinical trial for the treatment of COVID-19 patients in severe and critical conditions; and which is in Phase IIa clinical trial for the prevention of Graft Versus Host Disease in allogeneic hematopoietic stem cell transplants (HSCT) patients. The company is also developing Allocetra for the prevention of complications associated with bone marrow transplantations and/or HSCT, and acute multiple organ failure. It also intends to develop its cell-based therapy to be combined with treatments of solid tumors via immune checkpoint rebalancing to enhance the efficacy of various anti-cancer therapies, including chimeric antigen receptor T-Cell therapy and therapies targeting T-Cell receptor therapy. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.


ENLV Latest News Stream


Event/Time News Detail
Loading, please wait...

ENLV Latest Social Stream


Loading social stream, please wait...

View Full ENLV Social Stream

ENLV Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year N/A
3-year N/A
5-year N/A
YTD N/A
2023 N/A
2022 N/A
2021 N/A
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!